Literature DB >> 2883905

The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies.

H Morgenstern, W M Glazer, D Niedzwiecki, P Nourjah.   

Abstract

To quantify the impact of chronic exposure to neuroleptic medication on the occurrence of tardive dyskinesia (TD), we conducted a meta-analysis of data collected from 21 studies published between 1966 and 1985. The observed prevalence of dyskinesia was greater among exposed subjects in all 21 studies; we estimate that, on the average, the occurrence rate was 2.9 times greater in exposed persons than would be expected if they had been unexposed. We estimate that 65 per cent of exposed cases and 51 per cent of all cases in these investigations were caused by long-term neuroleptic exposure. Among adult United States residents in 1980, we estimate that there were approximately 193,000 neuroleptic-induced TD cases of which about 60 per cent occurred in outpatients. We also observed substantial heterogeneity of effect (rate ratio) across studies, however, partially explained, by changes and differences in the rate of dyskinesia, by differences in the frequency of certain effect modifiers, and by differences in diagnostic methods. Methodologic limitations of the studies and their possible effects on our results are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883905      PMCID: PMC1647084          DOI: 10.2105/ajph.77.6.717

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  56 in total

Review 1.  Persistent dyskinesia.

Authors:  G E Crane
Journal:  Br J Psychiatry       Date:  1973-04       Impact factor: 9.319

2.  [On the problem of persistent extrapyramidal hyperkinesia following prolonged use of neuroleptics].

Authors:  R Degkwitz; K F Binsack; H Herkert; O Luxenburger; W Wenzel
Journal:  Nervenarzt       Date:  1967-04       Impact factor: 1.214

3.  Tardive dyskinesia and drug therapy in geriatric patients.

Authors:  G E Crane; R A Smeets
Journal:  Arch Gen Psychiatry       Date:  1974-03

4.  Phenothiazine-induced dyskinesia in nursing-home patients.

Authors:  D L Greenblatt; J R Dominick; B A Stotsky; A DiMascio
Journal:  J Am Geriatr Soc       Date:  1968-01       Impact factor: 5.562

5.  Patterns of psychotropic drug use for schizophrenia.

Authors:  E Laska; E Varga; J Wanderling; G Simpson; G W Logemann; B K Shah
Journal:  Dis Nerv Syst       Date:  1973 Aug-Sep

6.  Dyskinesia and neuroleptics.

Authors:  G E Crane
Journal:  Arch Gen Psychiatry       Date:  1968-12

7.  Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leucotomy.

Authors:  J P Demars
Journal:  J Nerv Ment Dis       Date:  1966-07       Impact factor: 2.254

8.  [Late extrapyramidal hyperkineses after prolonged neuroleptic therapy].

Authors:  H Hippius; J Lange
Journal:  Arzneimittelforschung       Date:  1970-07

9.  A study of facial dyskinesia in a mental hospital population.

Authors:  S Brandon; H A McClelland; C Protheroe
Journal:  Br J Psychiatry       Date:  1971-02       Impact factor: 9.319

10.  Choreiform movements as side effects of phenothiazine medication in geriatric patients.

Authors:  H Siede; H F Müller
Journal:  J Am Geriatr Soc       Date:  1967-06       Impact factor: 5.562

View more
  4 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 2.  A clinical guide to antipsychotic drugs.

Authors:  J T Schwartz; A W Brotman
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

3.  Prevalence of spontaneous dyskinesia in first episode, drug naive schizophrenia, and its relation to the positive and negative symptoms of schizophrenia.

Authors:  Samrat Singh Bhandari; Dipesh Bhagabati
Journal:  Open J Psychiatry Allied Sci       Date:  2016-12-30

4.  Tardive and spontaneous dyskinesia incidence in the general population.

Authors:  Ray M Merrill; Joseph L Lyon; Paul M Matiaco
Journal:  BMC Psychiatry       Date:  2013-05-28       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.